These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Prostate Trials Office research protocols. Yang Q; Donovan J; Abrams P BJU Int; 2000 Mar; 85 Suppl 1():58-65. PubMed ID: 10756708 [No Abstract] [Full Text] [Related]
5. An analysis of the costs of alternative treatments for benign prostatic hypertrophy. Vale JA; Bdesha AS; Witherow RO J R Soc Med; 1995 Nov; 88(11):644P-648P. PubMed ID: 8544151 [No Abstract] [Full Text] [Related]
6. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. DiSantostefano RL; Biddle AK; Lavelle JP BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339 [TBL] [Abstract][Full Text] [Related]
8. Benign prostatic hyperplasia. Melville A; Donovon J; Sheldon T; Peters T Qual Health Care; 1996 Jun; 5(2):111-9. PubMed ID: 10158589 [No Abstract] [Full Text] [Related]
9. [Treatments of benign prostatic hypertrophy and their cost-benefit relationship]. Rissanen P; Salo H; Helin-Salmivaara A; Tammela T Duodecim; 2000; 116(13):1419-26. PubMed ID: 12001365 [No Abstract] [Full Text] [Related]
10. Benign prostatic hyperplasia: counting the cost of its management. Kirk D; McNicholas TA BJU Int; 2010 Aug; 106(4):586. PubMed ID: 20653663 [No Abstract] [Full Text] [Related]
11. Benign prostatic hyperplasia: counting the cost of its management. Kirby RS; Kirby M; Fitzpatrick JM BJU Int; 2010 Apr; 105(7):901-2. PubMed ID: 20356323 [No Abstract] [Full Text] [Related]
12. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results. Blute M; Ackerman SJ; Rein AL; Beusterien K; Sullivan EM; Tanio CP; Strauss MJ; Manyak MJ Urology; 2000 Dec; 56(6):981-7. PubMed ID: 11113744 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Ackerman SJ; Rein AL; Blute M; Beusterien K; Sullivan EM; Tanio CP; Manyak MJ; Strauss MJ Urology; 2000 Dec; 56(6):972-80. PubMed ID: 11113743 [TBL] [Abstract][Full Text] [Related]
14. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. DiSantostefano RL; Biddle AK; Lavelle JP Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluations and randomized trials in spinal disorders: principles and methods. Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541 [TBL] [Abstract][Full Text] [Related]
16. Economic modeling to assess the costs of treatment for benign prostatic hyperplasia. Ansong KS Urology; 1996 Jan; 47(1):152. PubMed ID: 8560655 [No Abstract] [Full Text] [Related]
17. Patient information and consent in trials for the treatment of benign prostatic obstruction. Thorpe AC; Neal DE BJU Int; 2000 Mar; 85 Suppl 1():42-5. PubMed ID: 10756705 [No Abstract] [Full Text] [Related]
18. The prostate's economic squeeze. Smith MD; McGhan WF Bus Health; 1997 Jul; 15(7):40, 42. PubMed ID: 10169754 [No Abstract] [Full Text] [Related]
19. Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC). Kaplan AL; Agarwal N; Setlur NP; Tan HJ; Niedzwiecki D; McLaughlin N; Burke MA; Steinberg K; Chamie K; Saigal CS Healthc (Amst); 2015 Mar; 3(1):43-8. PubMed ID: 26179588 [TBL] [Abstract][Full Text] [Related]